Home / Brand archive
35 reported ongoing
47 records in this archive. Latest source date Aug 5, 2026.
FDA enforcement status can lag behind the recall lifecycle. An empty search or a reported termination is not a personal product-safety determination.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Class IIReported ongoing
Distribution: Nationwide within the U.S
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
Class IIReported ongoing
Distribution: Nationwide within the U.S
Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
Class IIReported ongoing
Distribution: Nationwide in the USA
Subpotent Drug: Due to oxidation caused by leakage of the contents of the capsules
Class IIReported ongoing
Distribution: US Nationwide.
Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.
Class IIIReported ongoing
Distribution: Nationwide in the USA
Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.
Class IIReported ongoing
Distribution: Nationwide in the USA
cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.
Class IIReported ongoing
Distribution: Nationwide in the US
cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.
Class IIReported ongoing
Distribution: Nationwide in the US
cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.
Class IIReported ongoing
Distribution: Nationwide in the US
Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity
Class IIReported ongoing
Distribution: Distributed Nationwide in the USA
Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity
Class IIReported ongoing
Distribution: Distributed Nationwide in the USA
Failed Impurity/Degradation Specifications
Class IIReported ongoing
Distribution: U.S. Nationwide
Failed Impurity/Degradation Specifications
Class IIReported ongoing
Distribution: U.S. Nationwide
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit
Class IIReported ongoing
Distribution: Nationwide in the USA
These examples come from this result page and are not a ranking of every recall reason.
This archive contains 47 records, including 35 with agency-reported ongoing status. The status field can be incomplete or stale. Open the current official notice and match your exact product.
Compare the product, firm and lot, date, model or serial identifiers with the notice. Use the label-check guide if you need help locating an identifier.
A name is a search match. The agency notice sets the affected products and identifiers. Do not assume that every item with the same name or brand belongs to the recall.
This search has source and keyword limits. Missing records or a missing lot code do not establish that a product is unaffected. Check source coverage and the agency's current notices.
Use monthly archives or the local search. The initial import covers records dated from October 2021 where available; each source's actual first and latest dates appear on the coverage page.